Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
Piotr Wysocki
Jun 12, 2024, 04:23 |
Insight
Piotr Wysocki: Physicial exercise reduces the risk of recurrence - TNBC and HER2+/HR- breast cancer
Piotr Wysocki recently posted on LinkedIn: "Soldato D et al. conducted a multicenter prospective cohort analysis…
Jun 5, 2024, 15:22 |
Insight
Piotr Wysocki: T-DXd in metastatic ER+/HER2-low breast cancer patients after endocrine treatment failure
Piotr Wysocki recently posted on LinkedIn: "Results of a Destiny-Breast06 trial have been presented by…
May 28, 2024, 13:25 |
Blog
Piotr Wysocki: Does participation in clinical trials improve patients' outcomes?
Piotr Wysocki recently posted on LinkedIn: "Iskander R et al. conducted a systematic review and meta-analysis…
May 24, 2024, 11:17 |
Insight
Piotr Wysocki: Patients with hypermutated colorectal cancer (POLE/D1pd) derive profound benefit from immunotherapy
Piotr Wysocki recently posted on LinkedIn: "Ambrosini N et al. published online (Annals of Oncology) the…
May 17, 2024, 17:53 |
Insight
Piotr Wysocki: Better responses to immunotherapy in NSCLC patients with rare EGFR mutation
Piotr Wysocki recently posted on LinkedIn: "The efficacy of immune checkpoint inhibitors (ICI) as monotherapy in…
May 17, 2024, 16:56 |
Insight
Piotr Wysocki: Liver resection vs nonsurgical treatments in patients with early multinodular hepatocellular cancer
Piotr Wysocki recently posted on LinkedIn: "Current Barcelona Clinic Liver Cancer guidelines do not support…
May 17, 2024, 12:54 |
Insight
Piotr Wysocki: Anti-HER2 treatment in patients with advanced biliary cancer
Piotr Wysocki recently posted on LinkedIn: "The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is…
May 14, 2024, 09:21 |
Drugs
Piotr Wysocki: Pembrolizumab prevents recurrence in BCG-resistant bladder cancer
Piotr Wysocki recently posted on LinkedIn: "Necchi A et al. published a phase II single-arm study…
May 10, 2024, 17:49 |
Drugs
Piotr Wysocki: Relatlimab does not improve the activity of nivolumab plus chemotherapy
Piotr Wysocki recently posted on LinkedIn: "RELATIVITY-060 was an open-label phase II study investigating the…
May 10, 2024, 10:27 |
Opinion
Piotr Wysocki: FDG PET can predict response to immunotherapy in melanoma patients
Piotr Wysocki recently posted on LinkedIn: "Anderson TM et al. published the results of a study…
2
3
4
5
6
All:
112
Posts:
31 - 40
ASTRO24: 15 Posts Not To Miss From Day 4
Top 100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2024
Paper Alert! Cutaneous Metastases in Thyroid Cancer: A Comprehensive Review of 136 Cases
ASTRO 24: 15 Posts Not to Miss From Day 3
Gavin Creel: Broadway Icon Dies After Battle with Rare Sarcoma at 48
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube